Nexstim Plc reported very promising clinical outcomes of the 187 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD). Treatment outcomes of these 187 patients were very good: 50.3% were in remission at end of treatment and 77.0 % had obtained a clinical response. These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7% and the patient-reported response rates were 41.5-56.4 %1. The patient-reported remission and response rates are also higher than those reported in a large >3800 patient series for patients completing clinical rTMS treatment (remission 29.7-36.2%, response 62.7-70.4%). The clinical outcomes of majority of the patients treated with SmartFocus® rTMS in the United States are being collected in a registry — the information is provided by participating clinical sites using Nexstim’s SmartFocus® technology. According to the registry, average general impression of receiving the SmartFocus® rTMS treatment reported by the patients completed the treatment was very positive with a mean score of 9.25 on a scale from 0 to 10 (10= best possible).